An Ethical Exploration of Barriers to Research on Controlled Drugs

American Journal of Bioethics

Volumn 16, Issue 4, 2016, Pages 36-47

  Andreae, Michael H ^a   Rhodes, Evelyn ^b   Bourgoise, Tyler ^b   Carter, George M ^c   White, Robert S ^d   Indyk, Debbie ^b   Sacks, Henry ^b   Rhodes, Rosamond ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Foundation for Integrative AIDS Research   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

biomedical research; confidentiality and privacy; human subjects research; informed consent; institutional review board; research ethics

Indexed keywords

CANNABIS; CONTROLLED SUBSTANCE; DIAMORPHINE; KETAMINE;

DRUG CONTROL; ETHICS; FREEDOM; HUMAN; INFORMED CONSENT; LEGISLATION AND JURISPRUDENCE; MEDICAL RESEARCH; PROFESSIONAL STANDARD; RESEARCH ETHICS; SOCIAL JUSTICE; TRENDS; UNITED KINGDOM; UNITED STATES;

BIOMEDICAL RESEARCH; CANNABIS; CONTROLLED SUBSTANCES; DRUG AND NARCOTIC CONTROL; ETHICS COMMITTEES, RESEARCH; ETHICS, RESEARCH; FREEDOM; HEROIN; HUMANS; INFORMED CONSENT; KETAMINE; SOCIAL JUSTICE; UNITED KINGDOM; UNITED STATES;

EID: 84961251933     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2016.1145282     Document Type: Article

References (105)

1. D.I.Abrams,, C.A.Jay, S.B.Shade, et al. 2007. Cannabis in painful HIV-associated sensory neuropathy A randomized placebo-controlled trial. Neurology 68(7): 515–21.
2. D.I.Abrams, 1998. Medical marijuana: Tribulations and trials. Journal of Psychoactive Drugs 30(2): 163–69.
3. S.K.Aggarwal,, G.T.Carter, M.D.Sullivan, C.ZumBrunnen, R.Morrill, and J.D.Mayer 2009.Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions. Journal of Opioid Management 5(3): 153–68.
4. M.Alexander, 2012. The new Jim Crow: Mass incarceration in the age of colorblindness. New York, NY: The New Press.
5. K.R.Alper,, H.S.Lotsof, G.M.Frenken, D.J.Luciano, and J.Bastiaans. 1999. Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions 8(3): 234–42.
6. E.E.Anderson,, and J.M.DuBois. 2012. IRB decision-making with imperfect knowledge: A framework for evidence-based research ethics review. Journal of Law, Medicine & Ethics 40(4): 951–69.
7. E.E.Anderson,, and J.M.DuBois. 2007. The need for evidence-based research ethics: A review of the substance abuse literature. Drug and Alcohol Dependence 86(2): 95–105.
8. E.E.Anderson,, S.Solomon, E.Heitman, et al. 2012. Research ethics education for community-engaged research: A review and research agenda. Journal of Empirical Research on Human Research Ethics 7(2): 3–19.
9. M.Andreae,, D.Indyk, G.Carter, M.Johnson, K.Suslov, and H.Sacks. 2012. Lack of guidelines for use of medical marijuana for HIV neuropathic pain. Presented to American Public Health Association 140th Annual Meeting. American Public Health Association. https://apha.confex.com/apha/140am/webprogram/Paper265212.html.
10. T.Antonio,, S.R.Childers, R.B.Rothman, et al. 2013. Effect of Iboga alkaloids on $$-opioid receptor-coupled G protein activation. PLoS ONE 8(10): e77262.
11. K.Bell,, and A.Salmon. 2011. What women who use drugs have to say about ethical research: Findings of an exploratory qualitative study. Journal of Empirical Research on Human Research Ethics 6(4): 84–98.
12. H.R.Bernard, 2011. Research methods in anthropology: Qualitative and quantitative approaches. Lanham, MD: Rowman Altamira.
13. V.Berridge, 2009. Heroin prescription and history. New England Journal of Medicine 361(8): 820–21.
14. J.Winter, 2006. Weed control. Boston Globe, May 28. Available at: http://www.boston.com
15. S.Blackstone, 2012. Portugal decriminalized all drugs eleven years ago and the results are staggering. Business Insider International. Available at: http://www.businessinsider. com/portugal-drug-policy-decriminalization-works-2012-7 (accessedApril20, 2015).
16. P.M.Boffey, 2014. What science says about marijuana. The New York Times, July 31, A22.
17. J.M.Bostwick, 2012. Blurred boundaries: The therapeutics and politics of medical marijuana. Mayo Clinic Proceedings 87(2): 172–86.
18. J.L.Bottorff,, L.J.L.Bissell, L.G.Balneaves, J.L.Oliffe, N.Capler, and J.Buxton. 2013. Perceptions of cannabis as a stigmatized medicine: A qualitative descriptive study. Harm Reduction Journal 10:2.
19. S.Bulling,, K.Schicker, Y.-W.Zhang, et al. 2012. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. Journal of Biological Chemistry 287(22): 18524–34.
20. A.Carter,, and W.Hall. 2008. The issue of consent in research that administers drugs of addiction to addicted persons. Account Research 15(4): 209–25.
21. X.Castells,, M.Casas, C.Pérez-Maсá, C.Roncero, X.Vidal, and D.Capellа. 2010. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews 2:CD007380.
22. L.C.Charland, 2002. Cynthia's dilemma: Consenting to heroin prescription. American Journal of Bioethics 2(2): 37–47.
23. D.K.Check,, L.E.Wolf, L.A.Dame, and L.M.Beskow. 2014. Certificates of confidentiality and informed consent: Perspectives of IRB chairs and institutional legal counsel. IRB 36(1): 1–8. PubMed PMID: 24649737; PubMed Central PMCID: PMC4076050.
24. P.J.Cohen, 2010. Medical marijuana 2010: It's time to fix the regulatory vacuum. Journal of Law Medicine & Ethics 38(3): 654–66.
25. P.J.Cohen, 2009a. Medical marijuana: The conflict between scientific evidence and political ideology. Part two of two. Journal of Pain & Palliative Care Pharmacotherapy 23 (2):120–140.
26. P.J.Cohen, 2009b. Medical marijuana: The conflict between scientific evidence and political ideology. Part one of two. Journal of Pain & Palliative Care Pharmacotherapy 23(1): 4–25.
27. C.M.Costantino,, A.Gupta, A.W.Yewdall, B.M.Dale, L.A.Devi, and B.K.Chen. 2012. Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS ONE 7(3): e33961.
28. L.Degenhardt,, and W.Hall. 2012. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379(9810): 55–70. doi: 10.1016/S0140-6736(11)61138-0.
29. F.Diep, 2011. Clearing the smoke. Scientific American 305(4): 21–21.
30. J.R.Donnelly, 2011. The need for ibogaine in drug and alcohol addiction treatment. Journal of Legal Medicine 32(1): 93–114.
31. Drug Enforcement Administration. 2007. United States Code (USC) controlled substances act: Section 812. Schedules of controlled substances. GPO Access [www.gpoaccess.gov]. Office of Diversion Control, Drug Enforcement Administration.
32. M.Earleywine, 2005. Understanding marijuana: A new look at the scientific evidence. New York, NY: Oxford University Press.
33. N.Elia,, and M.R.Tramèr. 2005. Ketamine and postoperative pain–a quantitative systematic review of randomised trials. Pain 113(1–2): 61–70.
34. R.J.Ellis,, W.Toperoff, F.Vaida, et al. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychopharmacology 34(3): 672–80.
35. Elsevier Connect. 2016. Research—not regulations—should guide medical marijuana use, journal editor says. Available at: https://www.elsevier.com/connect/research-not-regulations-should-guide-medical-marijuana-use-journal-editor-says.
36. N.B.Finnerup,, S.H.Sindrup, and T.S.Jensen. 2010. The evidence for pharmacological treatment of neuropathic pain. Pain 150(3): 573–81.
37. J.A.Fleming,, R.Byck, and P.G.Barash. 1990. Pharmacology and therapeutic applications of cocaine. Anesthesiology 73(3): 518–31.
38. S.Ghosh,, A.Chandran, and J.P.Jansen. 2012. Epidemiology of HIV-related neuropathy: A systematic literature review. AIDS Research and Human Retroviruses 28(1): 36–48.
39. D.T.Gilbert,, and J.E.Ebert. 2002. Decisions and revisions: The affective forecasting of changeable outcomes. Journal of Personality Social Psychology 82(4): 503–14.
40. M.Giles,, and C.Workman. 2009. Clinical manifestations and the natural history of HIV. In HIV Management in Australia, 125–131. New South Wales, Australia: Australian Society for HIV Medicine.
41. N.Gligorov, 2009. Reconsidering the impact of affective forecasting. Cambridge Quarterly of Healthcare Ethics 18(2): 166–173; discussion 174–166.
42. M.Gossop,, F.Keaney, P.Sharma, and M.Jackson. 2005. The unique role of diamorphine in British medical practice: A survey of general practitioners and hospital doctors. European Addiction Research 11(2): 76–82.
43. G.Greer,, and R.Tolbert. 1986. Subjective reports of the effects of MDMA in a clinical setting. Journal of Psychoactive Drugs 18(4): 319–27.
44. L.Grinspoon,, J.B.Bakalar, and R.Doblin. 1995. Marijuana, the AIDS wasting syndrome, and the U.S. government. New England Journal of Medicine 333(10): 670–71.
45. J.Halpern, and R.M.Arnold 2008. Affective forecasting: An unrecognized challenge in making serious health decisions. Journal of General Internal Medicine 23(10): 1708–1712.
46. S.D.Halpern,, J.H.T.Karlawish, D.Casarett, J.A.Berlin, and D.A.Asch. 2004. Empirical assessment of whether moderate payments are undue or unjust inducements for participation in clinical trials. Archives of Internal Medicine 164(7): 801–3.
47. M.Hamerle,, L.Ghaeni, A.Kowski, F.Weissinger, and M.Holtkamp. 2014. Cannabis and other illicit drug use in epilepsy patients. European Journal of Neurology 21(1): 167–70.
48. R.R.Hammer,, M.J.Dingel, J.E.Ostergren, K.E.Nowakowski, and B.A.Koenig. 2012. The experience of addiction as told by the addicted: Incorporating biological understandings into self-story. Culture Medicine and Psychiatry 36(4): 712–34.
49. R.D.Harrington,, J.A.Woodward, T.M.Hooton, and J.R.Horn. 1999. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Archives of Internal Medicine 159(18): 2221–24.
50. M.Iskedjian,, B.Bereza, A.Gordon, C.Piwko, and T.R.Einarson. 2007. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Current Medical Research and Opinion 23(1): 17–24.
51. R.Jacobson, 2014. Mystical medicine. Scientific American Mind 25(5): 24–24.
52. D.Kahneman,, and A.Tversky. 2000. Choices, values, and frames. New York, NY: Cambridge University Press.
53. E.T.Kavalali,, and L.M.Monteggia. 2012. Synaptic mechanisms underlying rapid antidepressant action of ketamine. American Journal of Psychiatry 169(11): 1150–56.
54. J.Kempner,, C.S.Perlis, and J.F.Merz. 2005. Ethics. Forbidden knowledge. Science 307(5711): 854.
55. J.M.Kendall,, B.C.Reeves, V.S.Latter, and Nasal Diamorphine Trial Group. 2001. Multicentre randomised controlled trial of nasal diamorphine for analgesia in children and teenagers with clinical fractures. British Medical Journal 322(7281): 261–65.
56. B.Kilmer,, J.P.Caulkins, B.M.Bond, and P.H.Reuter. 2010. Reducing drug trafficking revenues and violence in Mexico: Would legalizing marijuana in california help? Santa Monica, CA: RAND Corporation. Available at: http://www.rand.org/pubs/occasional_papers/OP325; also available in print form.
57. R.Klitzman, 2006. From “male bonding rituals” to “suicide Tuesday”: A qualitative study of issues faced by gay male ecstasy (MDMA) users. Journal of Homosexuality 51(3): 7–32.
58. R.Klitzman, 2013. How IRBs view and make decisions about coercion and undue influence. Journal of Medical Ethics 39(4): 224–29.
59. X.Koenig,, M.Kovar, S.Boehm, W.Sandtner, and K.Hilber. 2014. Anti-addiction drug ibogaine inhibits hERG channels: A cardiac arrhythmia risk. Addiction Biology 19(2): 237–39.
60. B.S.Koppel,, J.C.M.Brust, T.Fife, et al. 2014. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82(17): 1556–63.
61. S.M.Kousik,, T.Napier, and P.M.Carvey. 2012. The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. Frontiers in Pharmacology 3:121.
62. J.L.Kramer, 2015. Medical marijuana for cancer. Ca-A Cancer Journal for Clinicians 65(2): 109–22.
63. E.Largent,, C.Grady, F.G.Miller, and A.Wertheimer. 2013. Misconceptions about coercion and undue influence: Reflections on the views of IRB members. Bioethics 27(9): 500–7.
64. J.-H.Li,, B.Vicknasingam, Y.-W.Cheung, et al. 2011. To use or not to use: An update on licit and illicit ketamine use. Substance Abuse and Rehabilitation 2:11–20.
65. E.E.Lutge,, A.Gray, and N.Siegfried. 2013. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database of Systematic Reviews 4:CD005175.
66. M.E.Lynch,, and F.Campbell. 2011. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology 72(5): 735–44. doi: 10.1111/j.1365-2125.2011.03970.x. Review. PubMed PMID: 21426373; PubMed Central PMCID: PMC3243008.
67. R.Macklin, 1981. On paying money to research subjects: ‘Due’ and ‘undue’ inducements. IRB 3(5): 1–6.
68. E.May, 1972. Narcotics addiction and control in Great Britain. Dealing with drug abuse: A report to the Ford Foundation. New York, NY: Praeger.
69. W.B.McAllister, 2004. The global political economy of scheduling: The international–historical context of the Controlled Substances Act. Drug and Alcohol Dependence 76(1): 3–8.
70. R.J.McInnes,, E.Hillan, D.Clark, and H.Gilmour. 2004. Diamorphine for pain relief in labour: A randomised controlled trial comparing intramuscular injection and patient-controlled analgesia. BJOG 111(10): 1081–89.
71. A.M.Mondzac, 1984. In defense of the reintroduction of heroin into American medical practice and H.R. 5290—The Compassionate Pain Relief Act. New England Journal of Medicine 311(8): 532–35.
72. D.F.Musto, 1972. The marihuana tax act of 1937. Archives of General Psychiatry 26(2): 101–8.
73. G.G.Nahas,, and A.Greenwood. 1974. The first report of the National Commission on marihuana (1972): Signal of misunderstanding or exercise in ambiguity. Bulletin of the New York Academy of Medicine 50(1): 55–75.
74. M.Nuijten,, P.Blanken, W.van den Brink, and V.Hendriks. 2014. Treatment of crack-cocaine dependence with topiramate: A randomized controlled feasibility trial in The Netherlands. Drug and Alcohol Dependence 138: 177–84.
75. D.J.Nutt,, L.A.King, and D.E.Nichols. 2013. Effects of schedule I drug laws on neuroscience research and treatment innovation. Nature Neuroscience 14(8): 577–85. doi: 10.1038/nrn3530. Epub 2013 Jun 12
76. K.O'Keefe, 2013. State medical marijuana implementation and federal policy. Journal of Helath Care Law & Policy 16: 39.
77. E.Oviedo-Joekes,, S.Brissette, D.C.Marsh, et al. 2009. Diacetylmorphine versus methadone for the treatment of opioid addiction. New England Journal of Medicine 361(8): 777–86.
78. A.C.Parrott, 2007. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): An evidence-based review. Psychopharmacology (Berlin) 191(2): 181–93.
79. Publications.parliament.uk. 2015. House of Commons—Science and technology—Written evidence. Available at: http://www.publications.parliament.uk/pa/cm200506/cm (accessed January22, 2015).
80. J.Ransom, 1999. “Anslingerian” politics: The history of anti-marijuana sentiment in federal law and how Harry Anslinger's anti-marijuana politics continue to prevent the FDA and other medical experts from studying marijuana's medical utility. Available at: https://dash.harvard.edu/handle/1/8965561
81. R.Rhodes, 2002. Unsafe presumptions in clinical research. American Journal of Bioethics 2(2): 49–51.
82. Rhodes, R. 2006. Why test children for adult-onset genetic diseases? Mt Sinai Journal of Medicine 73(3): 609–616.
83. Rhodes, R. and J. J. Strain 2008. Affective forecasting and its implications for medical ethics. Cambridge Quarterly of Healthcare Ethics 17(1): 54–65.
84. Rhodes, R. and J. J. Strain. 2009. Further thoughts about affective forecasting biases in Medicine: A response to Nada Gligorov. Cambridge Quarterly of Healthcare Ethics 18(2): 174–176.
85. M.G.Roback,, J.E.Wathen, T.MacKenzie, and L.Bajaj. 2006. A randomized, controlled trial of i.v. versus i.m. ketamine for sedation of pediatric patients receiving emergency department orthopedic procedures. Annals of Emergency Medicine 48(5): 605–12.
86. K.Robertson,, C.Bayon, J.-M.Molina, et al. 2014. Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care 26(12): 1555–61.
87. S.Ross 2012. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatric Clinics of North America 35(2): 357–74. doi: 10.1016/j.psc.2012.04.002.
88. J.Savulescu, 2001. The fiction of“ undue inducement”: Why researchers should be allowed to pay participants any amount of money for any reasonable research project. American Journal of Bioethics 1(2): 1g–3g.
89. J.Sawynok, 2014. Topical and peripheral ketamine as an analgesic. Anesthesia and Analgesia 119(1): 170–178.
90. Scientific American. 2014. End the drug war's research bans. 310(2): 10. doi:10.1038/scientificamerican0214-10. Available at: http://www.scientificamerican.com/article/end-the-ban-on-psychoactive-drug-research/
91. B.Sessa, 2007. Is there a case for MDMA-assisted psychotherapy in the UK? Journal of Psychopharmacology 21(2): 220–24.
92. E.M.Silva,, C.C.Cirne-Santos, I.C.Frugulhetti, et al. 2004. Anti-HIV-1 activity of the Iboga alkaloid congener 18-methoxycoronaridine. Planta Medical 70(9): 808–12.
93. N.Sindicich,, L.Degenhardt, and W.Hall. 2010. The use of MDMA for therapeutic purposes. In L.Degenhardt and W.Hall, eds. The health and psychological effects of ecstasy (MDMA) use. Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.
94. J.Swartz, 2012. Substance abuse in America: A documentary and reference guide, 259. Westport, CT: Greenwood.
95. D.C.Turk,, M.C.Brody, and E.A.Okifuji. 1994. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain 59(2): 201–8.
96. United States Congress. 1980. Foreign Commerce. Subcommittee on Health. Therapeutic Use of Heroin: Hearing Before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, Second Session, on HR 7334. September 4, 1980.: US Government Printing Office, 1980.
97. N.D.Volkow,, R.D.Baler, W.M.Compton, and S.R.B.Weiss. 2014. Adverse health effects of marijuana use. New England Journal of Medicine 370(23): 2219–27.
98. M.A.Ware,, T.Wang, S.Shapiro, et al. 2010. Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. Canadian Medical Association Journal 182(14): E694–E701.
99. E.Wax-Thibodeaux, 2014. Federal research seeks alternatives to addictive opioids for veterans in pain. Washington Post. Avaialble at: https://www.washingtonpost.com/news/federal-eye/wp/2014/09/25/federal-research-seeks-alternatives-to-addictive-opioids-for-veterans-in-pain/
100. M.Y.K.Wee,, J.P.Tuckey, P.Thomas, and S.Burnard. 2011. The IDvIP trial: A two-centre randomised double-blind controlled trial comparing intramuscular diamorphine and intramuscular pethidine for labour analgesia. BMC Pregnancy Childbirth 11:51.
101. M.Y.K.Wee,, J.P.Tuckey, P.W.Thomas, and S.Burnard. 2014. A comparison of intramuscular diamorphine and intramuscular pethidine for labour analgesia: A two-centre randomised blinded controlled trial. BJOG 121(4): 456.
102. B.Wilsey,, T.Marcotte, R.Deutsch, B.Gouaux, S.Sakai, and H.Donaghe. 2013. Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain 14(2): 136–48.
103. T.D.Wilson,, T.Wheatley, J.M.Meyers, D.T.Gilbert DT, and D.Axsom. 2000. Focalism: A source of durability bias in affective forecasting. Journal of Personality and Social Psychology 78(5): 821–36.
104. G.L.Yau,, C.S.Jackman, P.L.Hooper, and T.G.Sheidow. 2011. Intravitreal injection anesthesia–comparison of different topical agents: A prospective randomized controlled trial. American Journal of Ophthalmology 151(2): 333–37.e2.
105. N.E.Zinberg,, and J.A.Robertson. 1972. Drugs and the public. New York, NY: Simon and Schuster.